Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Cancer Cell International

H uan-Rong Lan¹  Ke-Tao Jin²  Yu-Yao Liu²  Bo Chen³  Jie-Ping Yan⁴ 

[1] Department of Breast and Thyroid Surgery, Affiliated Jinhua Hosptial, Zhejiang University School of Medicine, Zhejiang Province, 312000, Jinhua, P.R. China;Department of Colorectal Surgery, Affiliated Jinhua Hosptial, Zhejiang University School of Medicine, Zhejiang Province, 312000, Jinhua, P.R. China;Department of Neurology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, 310014, Hangzhou, China;Department of Pharmacy, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, 310014, Hangzhou, China;

关键词: Colorectal cancer;    Immunotherapy;    Monoclonal antibody;    Chimeric antigen receptor (CAR) T cells;   

DOI  :  10.1186/s12935-021-01763-9

来源: Springer

【 摘 要 】

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide. Besides common therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, novel therapeutic approaches, including immunotherapy, have been an advent in CRC treatment. The immunotherapy approaches try to elicit patients` immune responses against tumor cells to eradicate the tumor. Monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR) T cells are two branches of cancer immunotherapy. MAbs demonstrate the great ability to completely recognize cancer cell-surface receptors and blockade proliferative or inhibitory pathways. On the other hand, T cell activation by genetically engineered CAR receptor via the TCR/CD3 and costimulatory domains can induce potent immune responses against specific tumor-associated antigens (TAAs). Both of these approaches have beneficial anti-tumor effects on CRC. Herein, we review the different mAbs against various pathways and their applications in clinical trials, the different types of CAR-T cells, various specific CAR-T cells against TAAs, and their clinical use in CRC treatment.

【 授权许可】

CC BY